CRNX Stock Summary and Trading Ideas (Crinetics Pharmaceuticals | NASDAQ:CRNX)

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

Crinetics Pharmaceuticals trades on the NASDAQ stock market under the symbol CRNX.

As of February 18, 2026, CRNX stock price declined to $43.45 with 707,519 million shares trading.

CRNX has a beta of 1.35, meaning it tends to be more sensitive to market movements. CRNX has a correlation of 0.15 to the broad based SPY ETF.

CRNX has a market cap of $4.45 billion. This is considered a Mid Cap stock.

Last quarter Crinetics Pharmaceuticals reported $143,000 in Revenue and -$1.38 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.12.

In the last 3 years, CRNX traded as high as $62.53 and as low as $15.23.

The top ETF exchange traded funds that CRNX belongs to (by Net Assets): VTI, VB, IWM, VBK, VXF.

CRNX has outperformed the market in the last year with a return of +23.4%, while the SPY ETF gained +13.8%. However, in the most recent history, CRNX shares have underperformed the stock market with its stock returning -0.2% in the last 3 month period and -13.0% for the last 2 week period, while SPY has returned +3.4% and -0.5%, respectively.

CRNX support price is $42.08 and resistance is $45.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRNX shares will trade within this expected range on the day.